Eplerenone for the Treatment of Central Serous Chorioretinopathy

Related Clinical Trial
Eplerenone Versus PDT: Comparative Study by OCTA Pilot Study on Deep Learning in the Eye Panmacular Versus Minimal Micropulse Laser Therapy in Central Serous Chorioretinopathy OCT in Rare Chorioretinal Diseases Evaluation of the Precision of the Microperimetry Function of the Spectral OCT/SLO Selective RPE Laser Treatment (SRT) for Various Macular Diseases Selective Retinal Pigment Epithelium Laser Therapy for Macular Disease of the Retina Non-damaging Retinal Laser Therapy With PASCAL Laser for Macular Diseases Intravitreal Bevacizumab for the Treatment of Central Serous Chorioretinopathy Photodynamic Therapy Using Verteporfin for Treatment of Chronic Central Serous Chorioretinopathy (CSC) Eye Patch Therapy for Central Serous Retinopathy (CSR) Multimodal Imaging in Central Serous Chorioretinopathy PRedictive Factors and Changes From Treatment in iPCV Versus CSR Versus nAMD With afLibercept Microperimetric Evaluation After Half-dose Photodynamic Therapy for Chronic Central Serous Chorioretinopathy Eplerenone For the Treatment of Chronic Central Serous Chorioretinopathy Pseudo-PDT in Central Serous Chorioretinopathy Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD Bevacizumab Versus Micropulse in Central Serous Chorioretinopathy (CSC) Study of Photodynamic Therapy (PDT) in Patients With Central Serous Chorioretinopathy (CSC) Selective Retina Therapy With Real-Time Feedback-Controlled Dosimetry for Treating Acute Idiopathic Central Serous Chorioretinopathy in Korean Patients Selective Retina Therapy (SRT) in Patients With Idiopathic Central Serous Retinopathy Effects of OCTA-guided PDT in Acute CSC Efficacy and Safety of Intravitreal Aflibercept Injection for Subacute Central Serous Chorioretinopathy Photodynamic Therapy Versus Eplerenone: Treatment Trial for Chronic Central Serous Chorioretinopathy Micropulse 577nm Laser vs Traditional Laser Treatment in Central Serous Chorioretinopathy The Changes of Retinal Capillaries After Half-dose PDT Measured by OCTA in Eyes With CSC Ranibizumab Versus Low-fluence Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinopathy Treatment Trial for Acute Central Serous Chorioretinopathy The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy Eplerenone Treatment for Chronic Central Serous Chorioretinopathy in Hungarian Population A Pilot Study of the Treatment of Central Serous Chorioretinopathy With Ketoconazole Selective Retina Therapy With ‘R:GEN’ in Patients With Central Serous Chorioretinopathy 577nm Micropulse Laser vs Half-dose Photodynamic Therapy on Acute Central Serous Chorioretinopathy Central Serous Chorioretinopathy: Etiology, Course and Prognosis A Study of the Beneficial Effects of Eplerenone on Central Serous Chorioretinopathy Treatment of Chronic Central Serous Chorioretinopathy Via Electromagnetic Stimulation and Platelet- Rich Plasma Brinzolamide for the Treatment of Chronic Central Serous Chorioretinopathy The Effect of Therapy With Bevacizumab in Chronic Central Serous Chorioretinopathy Eplerenone for the Treatment of Central Serous Chorioretinopathy Micropulse Diode Laser Treatment for Chronic Central Serous Chorioretinopathy Comparison of Multifocal Electroretinogram Assessment in Chronic Central Serous Chorioretinopathy (CSC) Between Laser Treatment Group and Photodynamic Therapy Group in Chronic Central Serous Chorioretinopathy Study on the Use of Micropulse Laser to Treat Central Serous Chorioretinopathy Optical Coherence Tomography Angiography (OCT-A) and Central Serous Chorioretinopathy (CSC) Intravitreal Ranibizumab Treatment of Central Serous Chorioretinopathy Effect of Helicobacter Pylori Treatment on Idiopathic Central Serous Chorioretinopathy (ICSCR) Treatment of Chronic Central Serous Chorioretinopathy With Open-Label Anecortave Acetate Short-Term Oral Mifepristone for Central Serous Chorioretinopathy Methotrexate for Central Serous Chorioretinopathy Treatment Trial Central Serous Chorioretinopathy Treated by Modified Photodynamic Therapy Prospective Randomized Controlled Treatment Trial for Chronic Central Serous Chorioretinopathy The Safe Effective Light Dose of Photodynamic Therapy for Chronic Central Serous Chorioretinopathy Eplerenone for Central Serous Chorioretinopathy High-dose Antioxidants for Central Serous Chorioretinopathy

Brief Title

Eplerenone for the Treatment of Central Serous Chorioretinopathy

Official Title

Eplerenone for the Treatment of Central Serous Chorioretinopathy

Brief Summary

      To test the effect oral eplerenone versus placebo in patients with central serious
      chorioretinopathy .
    

Detailed Description

      To evaluate the effect of oral eplerenone compared to placebo in patients with central serous
      chorioretinopathy (CSCR) on sub-foveal (small part of retina) fluid using optical coherence
      tomography (OCT).
    


Study Type

Interventional


Primary Outcome

Mean Change in Maximal Subretinal Fluid Height Based on Spectral Domain Optical Coherence Tomography (OCT) Measurement.

Secondary Outcome

 Mean Change in Subfoveal Fluid Height Based on OCT Measurement

Condition

Central Serous Chorioretinopathy

Intervention

25mg Eplerenone

Study Arms / Comparison Groups

 25mg Eplerenone- Chronic CSCR Diagnosis
Description:  Dosing will begin at 25mg Eplerenone taken orally , one time, each day for 58 days. Throughout the 58 day treatment period dosage will be adjusted. The adjustment will be based on serum potassium and creatine levels from blood draws done at Day 12 and Day 33. From the 25 mg starting dosage, the dosage will either be increased to 50 mg a day or reduced to placebo, one time, each day.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

108

Start Date

October 2013

Completion Date

May 2015

Primary Completion Date

March 2015

Eligibility Criteria

        Inclusion Criteria:

          -  Age 18 and over

          -  Ability to give written informed consent

          -  Sub-retinal fluid under fovea seen on OCT

          -  Diagnosis of central serous chorioretinopathy (CSCR): classification is at the
             discretion of the investigator, but general guidelines are

               1. Acute- first episode or symptoms less than one month prior to presentation

               2. Chronic- previously documented sub-foveal fluid, any prior treatment, symptoms
                  for over 3 months, or <50% reduction in fluid thickness on OCT after 3 months.

        Exclusion Criteria:

          -  Age under 18

          -  Impaired decision-making ability

          -  At initial laboratory screening serum potassium >5.5 milliequivalent (mEq)/L

          -  At initial laboratory screening serum creatinine >2 mg/dL in men and >1.8 mg/dL in
             women or decreased renal function by creatinine clearance less than 50 mL/min

          -  Absence of sub-foveal fluid

          -  Any patient with prior treatment for CSCR within 3 months of enrollment

          -  Patients taking potassium supplements or potassium-sparing diuretics spironolactone,
             amiloride, and triamterene and/or potent CYP3A4 (cytochrome) inhibitors (amifostine,
             cyclosporine, fluconazole, itraconazole, ketoconazole, mifepristone, posaconazole,
             potassium salts, rituximab, tacrolimus, voriconazole nefazodone, troleandomycin,
             clarithromycin, ritonavir, and nelfinavir)

          -  Women who are pregnant or are actively trying to conceive

          -  Patients with type 1 or type 2 diabetes
      

Gender

All

Ages

18 Years - N/A

Accepts Healthy Volunteers

No

Contacts

Mitchell Fineman, MD, , 

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT01990677

Organization ID

ECSelsior

Secondary IDs

ESCelsior2013

Responsible Party

Principal Investigator

Study Sponsor

Wills Eye

Collaborators

 Mid Atlantic Retina

Study Sponsor

Mitchell Fineman, MD, Principal Investigator, Mid Atlantic Retina


Verification Date

October 2018